Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Trading banner 1
Trading banner 2
Trading banner 3
Trading banner 4
Trading banner 5
Trading banner 6
Trading banner 7
Trading banner 8
Trading banner 9
Asset icon - trade crypto, stocks, and gold on Pluang

Buy & Sell Summit Therapeutics Inc (SMMT) – Summit Therapeutics Inc Price Today

24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

SMMT stock surged 15.62% to $24.42, driven by positive FDA acceptance of its ivonescimab BLA for lung cancer. Despite negative profitability metrics, analyst consensus remains strongly bullish with a $32.50 price target. The company's pipeline progress overshadows recent quarterly losses, positioning it as a high-risk, high-reward biotech play.
Outlook hinges on ivonescimab's regulatory success, offering significant upside if approved. Key risks include clinical trial setbacks and cash burn. Investors should weigh the strong analyst support against the company's current lack of profitability and elevated financial risks.
Read full analysis

Key Stats

  • Market Cap
    $18.93B
  • Sector
    Health
  • 3M Drawdown
    -20.26%
  • Enterprise Value
    $18.24B
  • Dividend Yield
    -
  • Trading Activity
    100% Buy | 0% Sell
  • Typical Hold Time
    0 days
$25.15
52W Low: $13.85
05 Feb 2026
52W High: $36.7
24 Apr 2025

Summit Therapeutics Inc (SMMT) is currently valued at a market capitalization of $18.93B, with an enterprise value of $18.24B. Over the past 52 weeks, Summit Therapeutics Inc has traded between a low of $13.85 and a high of $36.7, highlighting its annual price range. Over the past three months, Summit Therapeutics Inc has recorded a drawdown of -20.26%, reflecting recent price volatility. On average, investors hold Summit Therapeutics Inc for approximately 0 days, indicating typical investor behavior on the platform.

About Summit Therapeutics Inc

Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.


Technical Indicators
|
|
|
Overall Summary
Bearish (3)Neutral (11)Bullish (9)

People also bought


US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions

Key Stats

  • Market Cap
    $18.93B
  • Sector
    Health
  • 3M Drawdown
    -20.26%
  • Enterprise Value
    $18.24B
  • Dividend Yield
    -
  • Trading Activity
    100% Buy | 0% Sell
  • Typical Hold Time
    0 days
$25.15
52W Low: $13.85
05 Feb 2026
52W High: $36.7
24 Apr 2025

Summit Therapeutics Inc (SMMT) is currently valued at a market capitalization of $18.93B, with an enterprise value of $18.24B. Over the past 52 weeks, Summit Therapeutics Inc has traded between a low of $13.85 and a high of $36.7, highlighting its annual price range. Over the past three months, Summit Therapeutics Inc has recorded a drawdown of -20.26%, reflecting recent price volatility. On average, investors hold Summit Therapeutics Inc for approximately 0 days, indicating typical investor behavior on the platform.

Let’s invest in this asset by signing up or download!